Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Talbot L, Loi K, Tam C, Rigas T
From patient eligibility to contract pharmacy restrictions, ongoing debates and lawsuits continue to shape the future of 340B
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 digital issues and online access to articles $119.00 per year only $9.92 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
For example, Ozempic is approved for diabetes, and Wegovy is approved for weight loss, reducing cardiovascular disease risk, and treating certain patients with fatty liver disease
doi:10.1177/0004867416652735CrossRefGoogle ScholarPubMed Millward, C, Ferriter, M, Calver, SJ, ConnellJones, GG
US$ 26.47
US$ 28.87
US$ 20.79
.jpg)
US$ 22.17
US$ 25.19
US$ 24.47
US$ 25.87
